Literature DB >> 12457311

Uniform long-term gene expression using adeno-associated virus (AAV) by ex vivo recirculation in rat-cardiac isografts.

B Asfour1, H A Baba, H H Scheld, R H Hruban, D Hammel, B J Byrne.   

Abstract

BACKGROUND: Gene therapy in cardiovascular disease promises to be of great impact. The ideal vector for the therapeutic gene transfection remains to be determined. The aim of the present study was to investigate the efficacy of gene transfer using adeno-associated virus vectors carrying the lacZ-reporter gene (AAV-lacZ) in a previously described coronary recirculation model.
METHODS: Beating Lewis rat hearts perfused with oxygenated Krebs-Henseleit solution were harvested, after which an atrial septal defect (ASD) was created. All vessels were tied, and AAV-lacZ was injected into the aortic root. The solution was recirculated through the ASD to the left side of the heart and pumped back to the coronary arteries by the left ventricle. Incubation was allowed for 20 min at 15 degrees C, and the hearts were subsequently transplanted heterotopically in syngeneic rats. Three increasing doses (109, 1,010, 1,011 e. u.) of AAV-lacZ virus vectors were used to study the rate of gene transfer. All hearts were harvested after 7-60 days and evaluated histologically for expression of the lacZ-gene.
RESULTS: Dose-dependent gene transfer was observed. Even after 60 days, there was no obvious decline in gene expression.
CONCLUSION: Adeno-associated virus vectors offer effective and uniform gene transfer in the myocardium after transcoronary injection and recirculation. Due to the lack of immune response previously described, no decrease in gene expression can be observed up to 60 days after injection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12457311     DOI: 10.1055/s-2002-35745

Source DB:  PubMed          Journal:  Thorac Cardiovasc Surg        ISSN: 0171-6425            Impact factor:   1.827


  5 in total

Review 1.  AAV vectors for cardiac gene transfer: experimental tools and clinical opportunities.

Authors:  Christina A Pacak; Barry J Byrne
Journal:  Mol Ther       Date:  2011-07-26       Impact factor: 11.454

Review 2.  Promise of adeno-associated virus as a gene therapy vector for cardiovascular diseases.

Authors:  Abesh Bera; Dwaipayan Sen
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

Review 3.  AAV hybrid serotypes: improved vectors for gene delivery.

Authors:  Vivian W Choi; Douglas M McCarty; R Jude Samulski
Journal:  Curr Gene Ther       Date:  2005-06       Impact factor: 4.391

4.  Role of cyclic AMP-dependent kinase response element-binding protein in recombinant adeno-associated virus-mediated transduction of heart muscle cells.

Authors:  Jarrod Dean; Jeremy Plante; Gordon S Huggins; Richard O Snyder; Ryuichi Aikawa
Journal:  Hum Gene Ther       Date:  2009-09       Impact factor: 5.695

5.  Gene transfer of heme oxygenase-1 using an adeno-associated virus serotype 6 vector prolongs cardiac allograft survival.

Authors:  Jacqueline M Evans; Sonia Navarro; Tomoko Doki; John M Stewart; Noboru Mitsuhashi; Mary Kearns-Jonker
Journal:  J Transplant       Date:  2012-10-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.